Helsinn Group Announces Oral Presentation of Data at AACR-NCI-EORTC Relating to a Potent and Highly Selective Investigational RET Inhibitor

Lugano, Switzerland, Oct. 7 (Korea Bizwire) – Helsinn Group, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, today announces the acceptance of two abstracts on a potent and [...]